Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | Director | June 10, 2026 | June 12, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | March 02, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,168 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 14,083 · Balance 44,168 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 14,083 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,656 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Grant · Acquired 13,656 · Balance 13,656 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. |
| Stock Option (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2036-06-10 | Direct | 6,209 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Grant · Acquired 6,209 · Balance 6,209 F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.
F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date.
F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date.
REPLIGEN CORP
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,062 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Tax withholding · Disposed 9,897 · Balance 89,062 F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 15,046 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,086 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · derivative · entry 10 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,154 Underlying: Common Stock · 3,086 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,037 | $0.00 Strike: $24.98 | $0.00 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · derivative · entry 9 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,037 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,916 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · derivative · entry 8 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 7,916 shares Expires 2024-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 3,086 | $32.40 | $99,986.40 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 100 | $141.58 | $14,158.00 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,241 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,377 | $140.99 | $194,143.23 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,341 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F4 · price: $140.99 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.54 to $141.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 28,980 | $140.04 | $4,058,359.20 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,718 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F3 · price: $140.04 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.54 to $140.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 16,496 | $139.17 | $2,295,748.32 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,698 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F2 · price: $139.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.52 to $139.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 39,037 | $24.98 | $975,144.26 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2020 Filed May 27, 2020 01:27 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 7,916 | $16.55 | $131,009.80 |
DisclosureSEC source: 0000899243-20-014282 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 22:50 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 12,300 | $90.13 | $1,108,599.00 |
DisclosureSEC source: 0000899243-20-007236 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,241 F1 · kind: Sales of shares in the open market to cover tax liability resulting from the release of restricted stock units. F3 · price: $90.13 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.66 to $90.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 22:50 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 100 | $88.56 | $8,856.00 |
DisclosureSEC source: 0000899243-20-007236 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,541 F1 · kind: Sales of shares in the open market to cover tax liability resulting from the release of restricted stock units. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 22:50 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,090 | $88.20 | $184,338.00 |
DisclosureSEC source: 0000899243-20-007236 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,641 F1 · kind: Sales of shares in the open market to cover tax liability resulting from the release of restricted stock units. F2 · price: $88.20 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.51 to $88.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 00:37 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 18,128 | $0.00 Strike: $86.10 | $0.00 |
DisclosureSEC source: 0000899243-20-006614 · doc4.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,128 Underlying: Common Stock · 18,128 shares Expires 2030-02-27 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 27, 2021, February 27, 2022 and February 27, 2023. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 00:37 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 18,583 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006614 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,731 F1 · shares: Mr. Hunt was awarded 18,583 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,594 | $86.10 | $137,243.40 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,148 F4 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F6 · price: $86.10 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.75 to $86.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,881 | $86.86 | $163,383.66 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,742 F4 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F5 · price: $86.86 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.75 to $86.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,210 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · derivative · entry 9 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,917 Underlying: Common Stock · 10,210 shares Expires 2024-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,735 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · derivative · entry 8 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,240 Underlying: Common Stock · 11,735 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 10,210 | $16.55 | $168,975.50 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,624 | $90.22 | $146,517.28 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,413 F3 · price: $90.22 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 8,412 | $91.66 | $771,043.92 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,037 F2 · price: $91.66 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.07 to $92.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,699 | $92.34 | $156,885.66 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,449 F1 · price: $92.34 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.10 to $92.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:39 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 11,735 | $32.40 | $380,214.00 |
DisclosureSEC source: 0000899243-20-006064 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 22:02 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0000899243-19-024058 · doc4.xml · derivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,127 Underlying: Common Stock · 20,000 shares Expires 2024-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 22:02 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 452 | $83.72 | $37,842.12 |
DisclosureSEC source: 0000899243-19-024058 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,413 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F4 · price: $83.7215 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.54 to $83.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 22:02 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,510 | $83.01 | $208,349.33 |
DisclosureSEC source: 0000899243-19-024058 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,865 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F3 · price: $83.0077 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.48 to $83.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 22:02 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 638 | $81.82 | $52,198.23 |
DisclosureSEC source: 0000899243-19-024058 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,375 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F2 · price: $81.8154 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.315 to $82.305, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 22:02 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 20,000 | $16.55 | $331,000.00 |
DisclosureSEC source: 0000899243-19-024058 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:58 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 36 | $90.31 | $3,251.16 |
DisclosureSEC source: 0000899243-19-023324 · doc4.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,013 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:58 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 288 | $89.27 | $25,709.59 |
DisclosureSEC source: 0000899243-19-023324 · doc4.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,049 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F7 · price: $89.2694 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.26 to $89.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:58 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 222 | $86.26 | $19,149.63 |
DisclosureSEC source: 0000899243-19-023324 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,337 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F6 · price: $86.2596 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.985 to $86.465, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:58 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 740 | $84.64 | $62,631.97 |
DisclosureSEC source: 0000899243-19-023324 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,559 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F5 · price: $84.6378 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.095 to $85.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:58 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,751 | $83.05 | $145,418.97 |
DisclosureSEC source: 0000899243-19-023324 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,299 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F4 · price: $83.0491 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.655 to $83.485, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:58 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,926 | $82.15 | $404,683.71 |
DisclosureSEC source: 0000899243-19-023324 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,050 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F3 · price: $82.1526 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.645 to $82.615, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:58 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,131 | $81.26 | $335,675.97 |
DisclosureSEC source: 0000899243-19-023324 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,976 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F2 · price: $81.2578 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.645 to $81.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 12:20 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 500 | $60.91 | $30,457.00 |
DisclosureSEC source: 0000899243-19-008472 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,107 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F4 · price: $60.9140 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.89 to $60.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 12:20 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,009 | $60.45 | $242,362.89 |
DisclosureSEC source: 0000899243-19-008472 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,607 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F3 · price: $60.4547 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.87 to $60.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 12:20 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 10,041 | $59.24 | $594,812.77 |
DisclosureSEC source: 0000899243-19-008472 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,616 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on September 21, 2018. F2 · price: $59.2384 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.87 to $59.835, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 05, 2019 Filed Mar 5, 2019 22:35 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 13,000 | $58.50 | $760,500.00 |
DisclosureSEC source: 0000899243-19-006157 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,657 F1 · kind: Sale of 13,000 shares in the open market to cover tax liability resulting from the release of restricted stock units. F2 · price: $58.50 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.17 to $59.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:52 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 21,651 | $0.00 Strike: $59.52 | $0.00 |
DisclosureSEC source: 0000899243-19-005884 · doc4.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,651 Underlying: Common Stock · 21,651 shares Expires 2029-02-28 F4 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 28, 2020, February 28, 2021 and February 28, 2022. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:52 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 7,475 | $59.01 | $441,099.75 |
DisclosureSEC source: 0000899243-19-005884 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,657 F2 · kind: Sale of 7,475 shares in the open market to cover tax liability resulting from the release of restricted stock units. F3 · price: $59.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.75 to $59.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:52 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 22,681 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005884 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,132 F1 · shares: Mr. Hunt was awarded 22,681 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 28, 2019 Filed Jun 11, 2019 22:59 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 21,756 | $0.00 Strike: $59.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016500 · doc4a.xml · derivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,756 Underlying: Common Stock · 21,756 shares Expires 2019-02-28 F1 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 28, 2020, February 28, 2021 and February 28, 2022 Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:15 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,873 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0000899243-18-024274 · doc4.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,127 Underlying: Common Stock · 11,873 shares Expires 2024-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 10,000 shares vest and become exercisable on each of the following dates: 5/05/2015, 5/05/2016, 5/05/2017, 5/05/2018 and 5/05/2019. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:15 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 27,566 | $57.71 | $1,590,809.05 |
DisclosureSEC source: 0000899243-18-024274 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,451 F1 · shares: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 17, 2017. F2 · price: $57.7091 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.18 to $58.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:15 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 11,873 | $16.55 | $196,498.15 |
DisclosureSEC source: 0000899243-18-024274 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2018 Filed May 22, 2018 21:12 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 16,249 | $42.53 | $691,016.35 |
DisclosureSEC source: 0001140361-18-025220 · doc1.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,144 F1 · shares: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 17, 2017. F2 · price: $42.5267 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.37 to $42.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 09, 2018 Filed May 11, 2018 14:30 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 1,400 | $40.70 | $56,980.28 |
DisclosureSEC source: 0001140361-18-022906 · doc1.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,393 F1 · shares: Payment of tax liability made via forfeiture of 1,400 shares of Common Stock valued at a weighted average price of $40.7002 per share on May 9, 2018. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 02:21 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 285,563 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0001140361-18-012133 · doc1.xml · derivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,563 Underlying: Common Stock · 285,563 shares Expires 2028-03-01 F4 · derivative.exercise_date: The shares vest in equal annual installments over a nine-year period beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.